Comprehensive microRNA analysis in bleomycin-induced pulmonary fibrosis identifies multiple sites of molecular regulation.

The molecular mechanisms of lung injury and fibrosis are incompletely understood. MicroRNAs (miRNAs) are crucial biological regulators that act by suppressing their target genes and are involved in a variety of pathophysiological processes. To gain insight into miRNAs in the regulation of lung fibrosis, total RNA was isolated from mouse lungs harvested at different days after bleomycin treatment, and miRNA array with 1,810 miRNA probes was performed thereafter. MiRNAs expressed in lungs with bleomycin treatment at different time points were compared with miRNAs expressed in lungs without bleomycin treatment, resulting in 161 miRNAs differentially expressed. Furthermore, miRNA expression patterns regulated in initial and late periods after bleomycin were identified. Target genes were predicted in silico for differentially expressed miRNAs, including let-7f, let-7g, miR-196b, miR-16, miR-195, miR-25, miR-144, miR-351, miR-153, miR-468, miR-449b, miR-361, miR-700, miR-704, miR-717, miR-10a, miR-211, miR-34a, miR-367, and miR-21. Target genes were then cross-referenced to the molecular pathways, suggesting that the differentially expressed miRNAs regulate apoptosis, Wnt, Toll-like receptor, and TGF-β signaling. Our study demonstrated a relative abundance of miRNA levels in bleomycin-induced lung fibrosis. The miRNAs and their potential target genes identified may contribute to the understanding of the complex transcriptional program of lung fibrosis.

[1]  Xiao-ming Meng,et al.  miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. , 2010, Journal of the American Society of Nephrology : JASN.

[2]  Oliver Eickelberg,et al.  Inhibition and role of let-7d in idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[3]  R. Homer,et al.  Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. , 2010, The Journal of clinical investigation.

[4]  Oliver Distler,et al.  MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. , 2010, Arthritis and rheumatism.

[5]  N. Kaminski,et al.  miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis , 2010, The Journal of experimental medicine.

[6]  R. Khanin,et al.  Dynamic Changes in Lung MicroRNA Profiles During the Development of Pulmonary Hypertension due to Chronic Hypoxia and Monocrotaline , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Robert H. Jenkins,et al.  Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[8]  J. Rosenbloom,et al.  Narrative Review: Fibrotic Diseases: Cellular and Molecular Mechanisms and Novel Therapies , 2010, Annals of Internal Medicine.

[9]  Kazuhiro Yoshida,et al.  Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. , 2010, The Lancet. Oncology.

[10]  P. Meda,et al.  Involvement of MicroRNAs in the Cytotoxic Effects Exerted by Proinflammatory Cytokines on Pancreatic β-Cells , 2010, Diabetes.

[11]  R. Stallings,et al.  miR-126 Is Downregulated in Cystic Fibrosis Airway Epithelial Cells and Regulates TOM1 Expression , 2010, The Journal of Immunology.

[12]  J. Araya,et al.  Fibrogenic reactions in lung disease. , 2010, Annual review of pathology.

[13]  Xinxia Peng,et al.  MicroRNA Expression and Virulence in Pandemic Influenza Virus-Infected Mice , 2010, Journal of Virology.

[14]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[15]  Zsolt Czimmerer,et al.  DIFFERENTIALLY EXPRESSED MicroRNAs IN SMALL CELL LUNG CANCER , 2009, Experimental lung research.

[16]  P. Barbry,et al.  Identification of Keratinocyte Growth Factor as a Target of microRNA-155 in Lung Fibroblasts: Implication in Epithelial-Mesenchymal Interactions , 2009, PloS one.

[17]  Chiwai Wong,et al.  Downregulations of B‐cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG‐05MG , 2009, International journal of cancer.

[18]  G. Jenkins,et al.  Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis. , 2009, Biochemical Society transactions.

[19]  I. Rigoutsos New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites. , 2009, Cancer research.

[20]  M. Wolzt,et al.  In vivo profile of the human leukocyte microRNA response to endotoxemia. , 2009, Biochemical and biophysical research communications.

[21]  R. Chambers Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? , 2008, British journal of pharmacology.

[22]  C. Marsh,et al.  The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. , 2008, Antioxidants & redox signaling.

[23]  P. Noble,et al.  Hyaluronan in tissue injury and repair. , 2007, Annual review of cell and developmental biology.

[24]  A. Greenberg,et al.  The role of TGF-beta in pulmonary fibrosis. , 2007, Ciba Foundation symposium.

[25]  P. Sime,et al.  TGF-β, Smad3 and the process of progressive fibrosis , 2007 .

[26]  Jeffrey T. Chang,et al.  GATHER: a systems approach to interpreting genomic signatures , 2006, Bioinform..

[27]  J. Horowitz,et al.  Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. , 2006, Proceedings of the American Thoracic Society.

[28]  A. Schnapp,et al.  Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. , 2006, American journal of respiratory and critical care medicine.

[29]  Johny Verschakelen,et al.  High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.

[30]  G. Prestwich,et al.  Regulation of lung injury and repair by Toll-like receptors and hyaluronan , 2005, Nature Medicine.

[31]  T. Oury,et al.  Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. , 2005, American journal of respiratory and critical care medicine.

[32]  J. Köhl,et al.  Opposing Regulatory Roles of Complement Factor 5 in the Development of Bleomycin-Induced Pulmonary Fibrosis1 , 2005, The Journal of Immunology.

[33]  R. Homer,et al.  Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fibrosis. , 2005, American journal of respiratory cell and molecular biology.

[34]  R. Homer,et al.  Idiopathic pulmonary fibrosis: new insights into pathogenesis. , 2004, Clinics in chest medicine.

[35]  Anton J. Enright,et al.  Human MicroRNA Targets , 2004, PLoS biology.

[36]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[37]  R. Homer,et al.  Regulation of pulmonary fibrosis by chemokine receptor CXCR3. , 2004, The Journal of clinical investigation.

[38]  M. Selman,et al.  The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. , 2003, American journal of respiratory cell and molecular biology.

[39]  Rakesh K. Kumar Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder , 2002, Respiratory Research.

[40]  V. Ambros microRNAs Tiny Regulators with Great Potential , 2001, Cell.

[41]  V. Ambros,et al.  An Extensive Class of Small RNAs in Caenorhabditis elegans , 2001, Science.

[42]  L. Lim,et al.  An Abundant Class of Tiny RNAs with Probable Regulatory Roles in Caenorhabditis elegans , 2001, Science.

[43]  B. Uhal,et al.  Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[44]  S. Nagata,et al.  Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. , 1999, The Journal of clinical investigation.

[45]  A. Boobis,et al.  Pulmonary fibrosis correlates with duration of tissue neutrophil activation. , 1998, American journal of respiratory and critical care medicine.

[46]  M. Kanehisa A database for post-genome analysis. , 1997, Trends in genetics : TIG.

[47]  T. Colby,et al.  Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[48]  R. Hällgren,et al.  Accumulation of hyaluronic acid in the alveolar interstitial tissue in bleomycin-induced alveolitis. , 1989, The American review of respiratory disease.

[49]  C. Haslett,et al.  The intensity of chronic lung inflammation and fibrosis after bleomycin is directly related to the severity of acute injury. , 1988, The American review of respiratory disease.

[50]  F. Orr,et al.  Effects of injury and repair of the pulmonary endothelium on lung metastasis after bleomycin , 1986, The Journal of pathology.

[51]  I. Adamson,et al.  Bleomycin-induced injury and metaplasia of alveolar type 2 cells. Relationship of cellular responses to drug presence in the lung. , 1979, The American journal of pathology.

[52]  Thomas D. Schmittgen,et al.  Integrating the MicroRNome into the study of lung disease. , 2009, American journal of respiratory and critical care medicine.

[53]  D. Warburton,et al.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? , 2008, The international journal of biochemistry & cell biology.

[54]  P. Sime,et al.  TGF-beta, Smad3 and the process of progressive fibrosis. , 2007, Biochemical Society transactions.

[55]  Naomi Altman,et al.  Replication, Variation and Normalisation in Microarray Experiments , 2005, Applied bioinformatics.

[56]  V. Poletti,et al.  Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. , 2003, The American journal of pathology.

[57]  V. Poletti,et al.  Aberrant Wnt/ (cid:1) -Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis , 2003 .

[58]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[59]  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). , 2000, American journal of respiratory and critical care medicine.

[60]  F. Marincola,et al.  Human Cancer Biology Microrna Expression Differentiates Histology and Predicts Survival of Lung Cancer Clinical Cancer Research Authors' Affiliations: Divisions of 1 Cancer Epidemiology and Genetics and 2 Cancer Treatment and Diagnosis , 2022 .